StoryTeller / Stories / Philip Morris International

Philip Morris International

PMI says it is building a future without cigarettes. This map sets that vision beside what regulators, health bodies and its own numbers show.

41 nodes59 edges19 sources5 guided storiestimelinelight theme

Open full page

Built from PMI’s public website, FDA and WHO statements, and independent analysis from Tobacco Tactics (University of Bath). PMI’s own figures are shown as PMI’s claims. Not affiliated with or endorsed by Philip Morris International. An independent StoryTeller study.

About this story

An independent StoryTeller study. Built 2026-10-02.

Every claim in it cites a dated source, and relationships the author interpreted are drawn dashed. Where the sources disagree, you see both.

Guided stories

  • The case for replacing cigarettesPMI’s own argument, in its own order: a billion smokers, a vision hedged by “not risk-free”, two product families, a revenue target and the latest progress figure.
  • A cigarette empireWhere the company came from, and the brand that still anchors it: from a London shop to the world’s best-selling cigarette.
  • How regulators and the WHO read IQOSOne product, two readings: the FDA authorizes IQOS with caveats and a narrow exposure claim, and the WHO says reduced exposure does not prove reduced risk.
  • Getting to the US marketThe US is the biggest prize for smoke-free products. The route took a spin-off, a rights dispute with Altria, a US$16 billion acquisition and two FDA decisions.
  • What PMI says and what the numbers showThe vision is a target, not yet a fact. This path sets PMI’s own progress figure beside independent reporting on cigarette revenue, volumes and messaging.

Sources (19)